PMID- 9551875
OWN - NLM
STAT- MEDLINE
DCOM- 19980612
LR  - 20191102
IS  - 0803-7051 (Print)
IS  - 0803-7051 (Linking)
VI  - 7
IP  - 1
DP  - 1998 Jan
TI  - Comparison of the angiotensin II receptor antagonist irbesartan with atenolol for 
      treatment of hypertension.
PG  - 31-7
AB  - In this multicenter, double-blind study, the antihypertensive efficacy and safety 
      of irbesartan were compared with those of atenolol in patients with 
      mild-to-moderate hypertension. Following a 4- to 5-week placebo lead-in period, 
      231 patients with seated diastolic blood pressure (SeDBP) 95-110 mmHg were 
      randomized to irbesartan 75 mg or atenolol 50 mg once daily for 24 weeks. Doses 
      were doubled at Week 6 for SeDBP > or = 90 mmHg. At Week 12, or anytime 
      thereafter, doses were doubled for SeDBP > or = 90 mmHg if not done at Week 6, 
      and hydrochlorothiazide and then nifedipine were added. Efficacy was determined 
      by change from baseline in blood pressure and by therapeutic response rates. 
      Safety was assessed by monitoring adverse events (AEs). Both treatments 
      significantly lowered blood pressure from baseline. There were no significant 
      differences between treatment groups with respect to blood pressure changes or 
      therapeutic response. Atenolol significantly reduced seated heart rate compared 
      with irbesartan at Week 12. The incidences of serious AEs and discontinuations 
      due to AEs were approximately twice as high in the atenolol group compared with 
      the irbesartan group. Thus, in comparison to atenolol, irbesartan < or = 150 mg 
      provided at least equivalent blood pressure control while demonstrating an 
      excellent safety and tolerability profile.
FAU - Stumpe, K O
AU  - Stumpe KO
AD  - Medizinische Universitatspoliklinik Bonn, Germany.
FAU - Haworth, D
AU  - Haworth D
FAU - Hoglund, C
AU  - Hoglund C
FAU - Kerwin, L
AU  - Kerwin L
FAU - Martin, A
AU  - Martin A
FAU - Simon, T
AU  - Simon T
FAU - Masson, C
AU  - Masson C
FAU - Kassler-Taub, K
AU  - Kassler-Taub K
FAU - Osbakken, M
AU  - Osbakken M
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - England
TA  - Blood Press
JT  - Blood pressure
JID - 9301454
RN  - 0 (Angiotensin Receptor Antagonists)
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Biphenyl Compounds)
RN  - 0 (Tetrazoles)
RN  - 50VV3VW0TI (Atenolol)
RN  - J0E2756Z7N (Irbesartan)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - *Angiotensin Receptor Antagonists
MH  - Antihypertensive Agents/adverse effects/*therapeutic use
MH  - Atenolol/adverse effects/*therapeutic use
MH  - Biphenyl Compounds/adverse effects/*therapeutic use
MH  - Blood Pressure/drug effects
MH  - Double-Blind Method
MH  - Female
MH  - Heart Rate/drug effects
MH  - Humans
MH  - Hypertension/*drug therapy/physiopathology
MH  - Irbesartan
MH  - Male
MH  - Middle Aged
MH  - Tetrazoles/adverse effects/*therapeutic use
MH  - Treatment Outcome
EDAT- 1998/04/29 00:00
MHDA- 1998/04/29 00:01
CRDT- 1998/04/29 00:00
PHST- 1998/04/29 00:00 [pubmed]
PHST- 1998/04/29 00:01 [medline]
PHST- 1998/04/29 00:00 [entrez]
AID - 10.1080/080370598437547 [doi]
PST - ppublish
SO  - Blood Press. 1998 Jan;7(1):31-7. doi: 10.1080/080370598437547.